i
Important informations
Instagram
Portal
Donate now

Our researchers

Aucun résultat

Anne Gatignol

Anne Gatignol, PhD

Molecular & Regenerative Medicine

AIDS/HIV, Infectious diseases, Innate immunity, RNA biology, RNA Interference, RNA Therapeutics, SARS-CoV-2, Virus-Cell interactions
  • Senior Investigator and head of the Virus-Cell Interactions Laboratory, Lady Davis Institute for Medical Research
  • Professor, Division of Infectious Diseases, Department of Medicine, McGill University
  • Associate Member, Department of Microbiology and Immunology, McGill University

Contact details

(514) 340-8260 ext. 25284 (office); (514) 340-8260 ext. 25251 (lab)
anne.gatignol@mcgill.ca

Snapshot

  • Anne Gatignol is an internationally recognized scientist in the field of virology for her work on virus-cell interactions during HIV replication.
  • She was the first to clone the cDNA coding for the cellular protein TRBP and to characterize its function in the cell and during HIV replication. TRBP has important cellular functions in development, cell growth, regulation of innate cell response to infection and in RNA interference.
  • Her current projects involve the innate cell response to HIV infection, the relationship between HIV, Zika virus and the RNA interference pathway, as well as the development of RNA-based technologies to counteract HIV and SARS-CoV-2 replication.

Important Links :

See Anne Gatignol's publications on PubMed

Major Research Activities

Anne Gatignol’s research focuses on the control of the cellular responses to HIV infection, which enhance or inhibit viral replication. She characterized several cellular factors that contribute to the regulation of PKR during HIV replication in lymphocytes and astrocytes.

 

Prof. Gatignol’s lab also studies the interactions between viruses and the components of the RNA interference machinery. She characterized the relationship between TRBP and Dicer proteins in the RNA-induced silencing complex. She is analyzing the modifications of the RNAi pathway induced by HIV and their pathological consequences.

 

Prof. Gatignol’s lab also develops RNA-based technologies to target HIV, SARS-CoV-2 and their cellular cofactors to inhibit viral replication. The aim of this project is to use the active anti-HIV molecules expressed on a lentiviral vector for use in gene therapy and to develop RNA therapeutics against SARS-CoV-2 to be used intranasally as an antiviral treatment.

Recent Publications and References

LDI logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.